Nektar Therapeutics
Price
OptionsOpen the Sheet →FilingsNewest: 8-K, Regulation FD disclosureOct 1 →InsidersNo open-market buys. 3 insiders sold $2.0M, 6 of 13 sales on a 10b5-1 plan.→HoldersFMR 24.9%Two Seas Capital 15.2%BlackRock 14.4%→Financing →PeersClosest companies: INCY, PTGX, VKTX→
From the filings
Figures
- Revenue
- $54.6Mlast 12 months
- Net income
- −$157.1Mlast 12 months
- Operating cash flow
- −$203.8Mlast 12 months
- Cash and equivalents
- $39.3Mat the last balance sheet
- Shares outstanding
- 20.4M shareson issue